Desirudin  (Synonyms: CGP 39393; Revasc)

Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction^[1][2].

ED50: 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)^[2].

Desirudin (CGP 39393, 0.75-3.0 mg/kg, a bolus plus infusion administration, dogs model of cardiopulmonary bypass) is effective in Inhibiting clot formation^[1].
Desirudin (0.01-1 mg/kg, Intravenous injections and subcutaneous injection, rat shunt model) inhibits thrombus development with ED₅₀ values of 0.3 mg/kg (i.v.) and 1.0 mg/kg (s.c.), and inhibits venous stasis thrombosis with ED₅₀ values of 0.01 mg/kg (i.v.) and 0.45 mg/kg (s.c.)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

120993-53-5

[desirudin]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. J M Walenga, et al. Evaluation of CGP 39393 as the Anticoagulant in Cardiopulmonary Bypass Operation in a Dog Model. Ann Thorac Surg. 1994 Dec;58(6):1685-9.  [Content Brief]

  [2]. M D Talbot, et al. Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost. 1989 Feb 28;61(1):77-80.  [Content Brief]